Teton Advisors Inc. Reduces Holdings in BioScrip Inc (BIOS)
Teton Advisors Inc. lowered its stake in BioScrip Inc (NASDAQ:BIOS) by 4.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 647,100 shares of the company’s stock after selling 28,000 shares during the period. Teton Advisors Inc.’s holdings in BioScrip were worth $1,883,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Gabelli Funds LLC increased its holdings in shares of BioScrip by 2.0% in the fourth quarter. Gabelli Funds LLC now owns 10,357,832 shares of the company’s stock valued at $30,141,000 after buying an additional 205,379 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of BioScrip in the third quarter valued at $857,000. Highbridge Capital Management LLC bought a new position in shares of BioScrip in the third quarter valued at $153,000. Royce & Associates LP bought a new position in shares of BioScrip in the third quarter valued at $481,000. Finally, Engineers Gate Manager LP bought a new position in shares of BioScrip in the third quarter valued at $449,000. 84.53% of the stock is currently owned by institutional investors.
In other news, CEO Daniel E. Greenleaf acquired 15,000 shares of the stock in a transaction on Thursday, November 9th. The shares were purchased at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the transaction, the chief executive officer now owns 31,000 shares in the company, valued at approximately $62,930. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.80% of the company’s stock.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The business had revenue of $198.70 million for the quarter, compared to analysts’ expectations of $202.91 million. During the same quarter last year, the firm posted ($0.12) EPS. The business’s quarterly revenue was down 11.5% on a year-over-year basis. equities analysts anticipate that BioScrip Inc will post -0.63 earnings per share for the current year.
BIOS has been the topic of several research reports. BidaskClub raised BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. SunTrust Banks set a $4.00 price target on BioScrip and gave the company a “buy” rating in a report on Thursday, December 21st. Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Finally, ValuEngine raised BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, November 30th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $3.63.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip Inc (NASDAQ:BIOS).
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.